Assessing consistent treatment effect in a multi‐regional clinical trial: a systematic review

A key issue in multi-regional clinical trials (MRCTs) is how to assess the consistency of treatment effect across regions, although there is no a priori reason to believe that the treatment effect should vary across the regions. In this article, we define the research question as an assessment of overall consistency across all regions for which all regions are considered equally important. This is different from the region/country-specific analyses (e.g. US vs Non-US), which are frequently requested by local regulatory agencies and usually performed for multiple agencies. We provide a systematic review of methods that may potentially be used for assessing consistency across regions, including commonly used quantitative/qualitative interaction tests, Japanese Pharmaceutical Medical Device Agency (PMDA) Methods 1 & 2, and those proposed for different purposes (e.g. bridging studies, meta-analysis, and vaccine lot consistency, among others). These methods are classified into three groups: global methods, multivariate quantitative methods, and multivariate qualitative methods. A case study is used to illustrate these methods. We also provide recommendations on how to choose appropriate methods and incorporate them in the study design.

[1]  Shein-Chung Chow,et al.  ASSESSING SENSITIVITY AND SIMILARITY IN BRIDGING STUDIES , 2002, Journal of biopharmaceutical statistics.

[2]  D. Altman,et al.  Measuring inconsistency in meta-analyses , 2003, BMJ : British Medical Journal.

[3]  D. DeMets,et al.  Statistical issues relating to international differences in clinical trials. , 2001, American heart journal.

[4]  M H Gail,et al.  A comparison of the power of two tests for qualitative interactions. , 1993, Statistics in medicine.

[5]  W. G. Cochran The combination of estimates from different experiments. , 1954 .

[6]  H Wedel,et al.  Challenges of subgroup analyses in multinational clinical trials: experiences from the MERIT-HF trial. , 2001, American heart journal.

[7]  R Dietz,et al.  Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group. , 2000, JAMA.

[8]  J. Tukey,et al.  Tests for qualitative treatment-by-centre interaction using a 'pushback' procedure. , 1993, Statistics in medicine.

[9]  Hiroyuki Uesaka,et al.  Sample Size Allocation to Regions in a Multiregional Trial , 2009, Journal of biopharmaceutical statistics.

[10]  Hui Quan,et al.  Sample size considerations for Japanese patients in a multi‐regional trial based on MHLW guidance , 2009, Pharmaceutical statistics.

[11]  R. Califf,et al.  Geographic variability in outcomes within an international trial of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes. Results from PURSUIT. , 2000, European heart journal.

[12]  J. Fleiss,et al.  Analysis of data from multiclinic trials. , 1986, Controlled clinical trials.

[13]  K. Swedberg,et al.  Continental differences in clinical characteristics, management, and outcomes in patients hospitalized with worsening heart failure results from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) program. , 2008, Journal of the American College of Cardiology.

[14]  S. Pocock,et al.  Subgroup analysis, covariate adjustment and baseline comparisons in clinical trial reporting: current practiceand problems , 2002, Statistics in medicine.

[15]  P. Lachenbruch,et al.  Lot Consistency as an Equivalence Problem , 2004, Journal of biopharmaceutical statistics.

[16]  Christy Chuang-Stein,et al.  An Approach to Rationalize Partitioning Sample Size into Individual Regions in a Multiregional Trial , 2008 .

[17]  James J. Chen,et al.  Sample Size Requirements for Evaluation of Bridging Evidence , 2002 .

[18]  A. Vickers,et al.  Do certain countries produce only positive results? A systematic review of controlled trials. , 1998, Controlled clinical trials.

[19]  N. Laird,et al.  Meta-analysis in clinical trials. , 1986, Controlled clinical trials.

[20]  M. Gail,et al.  Testing for qualitative interactions between treatment effects and patient subsets. , 1985, Biometrics.

[21]  H. White,et al.  Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: the HERO-2 randomised trial , 2001, The Lancet.

[22]  Y. Chen,et al.  Testing for Crossover of Two Hazard Functions Using Gail and Simon's Method , 2006, Journal of biopharmaceutical statistics.